- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02661373
First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor
Phase 1a, First-In-Human, Dose-Escalation Study of (+)-SJ000557733 (SJ733), an Oral, Novel Inhibitor of Plasmodium Falciparum Plasma Membrane Protein PfATP4
Malaria is an infectious disease caused by a parasite that is passed to humans when an infected mosquito bites a person. About 3.4 billion people live in areas of the world where malaria is regularly found. In many countries, malaria is one of the leading causes of illness and death. Despite this, there are a limited number of drugs, called antimalarials, that can be used to treat malaria and increasing reports of resistance to existing antimalarials.
The purpose of this research study is to test a new experimental antimalarial drug called SJ733 to first assess its safety, tolerability and blood levels in healthy adult volunteers.
Single-dose, multi-dose and boosted-dose cohorts (both single and multi-dose) will be studied. The pharmacoenhancer (booster), cobicistat, will be given in combination with SJ733 in the boosted dose-cohorts.
PRIMARY OBJECTIVES:
- To assess the preliminary safety and tolerability of escalating doses of antimalarial SJ733 in healthy human volunteers.
- To investigate the pharmacokinetic (PK) profile of escalating doses of antimalarial SJ733 and its metabolite in healthy human volunteers.
- To identify a dose of SJ733 that can be tested in a separate Phase 1b human malaria challenge study.
- To assess the preliminary safety and tolerability of SJ733 in healthy adult volunteers after multiple oral dosing.
- To assess the pharmacokinetics of SJ733 and its metabolite SJ506 after multiple dosing of SJ733 in healthy adult volunteers.
- To assess the preliminary safety and tolerability of escalating single oral doses of SJ733 in combination with cobicistat among healthy adult volunteers.
- To assess the pharmacokinetics of SJ733 and its metabolite SJ506 after single oral doses of SJ733 in combination with cobicistat among healthy adult volunteers.
- To assess the preliminary safety and tolerability of SJ733 in combination with cobicistat in healthy adult volunteers after multiple oral dosing.
- To assess the pharmacokinetics of SJ733 and its metabolite SJ506 after multiple dosing of SJ733 in combination with cobicistat among healthy volunteers.
SECONDARY OBJECTIVE:
- To assess the impact of food intake on the pharmacokinetic profile of antimalarial SJ733.
Study Overview
Detailed Description
This is a single site, Phase 1a, first-in-human, oral, primarily single-dose, dose escalation study of (+)-SJ000557733 (SJ733) in healthy adult volunteers. SJ733, is an investigational oral anti-malarial agent is a novel inhibitor of Plasmodium falciparum plasma membrane protein (PfATP4). Subjects meeting eligibility criteria will be enrolled using a leap frog, fixed dose escalation design with an adaptive component where 6 subjects are enrolled per dose cohort.
Following successful completion of the safety and pharmacokinetic (PK) assessment resulting from the single-dose escalation portion of the study, a three-dose cohort study will be undertaken. It includes once per day oral dosing for 3 consecutive days. Both single and multi-dose cohorts of SJ733 in combination with cobicistat (boosted cohorts) will also be completed.
After the study results from the single-dose cohorts of SJ733 in combination with cobicistat (boosted cohorts) were reviewed, multi-dose cohorts of SJ733 in combination with cobicistat (boosted cohorts) were not conducted and Phase 2 study planning initiated.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult (as certified by comprehensive medical assessment including detailed history and complete physical examination), male or female, aged 18 to 55 years of age (inclusive) at screening
- At least 50 kg in weight and body mass index (BMI) between 18 and 34 kg/m^2
- Able and willing to provide informed consent and to be available for follow-up for the planned duration of the study
- If female, then not of child bearing potential (i.e. permanently sterilized hysterectomy or bilateral oophorectomy at least 6 months before screening; proper documentation required] and/or post-menopausal defined as 12 months with no menses without an alternative cause and with an estradiol level of < 30 pg/mL and follicle-stimulating hormone level of > 40 IU/L at screening)
- Sexually active males must agree to be abstinent or use condoms for the duration of the study.
- Screening laboratories (hematology, chemistries, venous methemoglobin level specified in schedule of evaluations) within normal institutional range or if outside the range, not clinically significant in the opinion of the investigator.
Inclusion Criteria for Participants in Single-dose Cohort Only::
- Agrees not to receive any vaccination within 7 days prior to Day 0 and through Day 7.
- Agrees not to use nonprescription drugs, including vitamins, antacids, and herbal and dietary supplements within 7 days prior to Day 0 and through Day 7. Acetaminophen may be used at doses of ≤ 1 g/day, and ibuprofen may be used at doses of ≤ 1.2 g/day.
- Agrees not to use nicotine containing products from screening through Day 7.
- Agrees not to consume alcohol for the 24 hours prior to Day 0 and through Day 7.
- Agrees not to eat pomegranate, grapefruit or other citrus fruits or drink their juices within 7 days prior to Day 0 and through Day 7.
- Agrees to limit caffeine to no more than 200 mg on Day 0.
- Agrees not to eat or drink (except water) for 10 hours before the Day 0 visit and have no water for the hour prior to dosing.
Exclusion Criteria:
- Presence of a significant medical or psychiatric condition that in the opinion of the investigator precludes participation in the study.
- Clinically significant abnormalities on physical examination that, in the opinion of the investigator, would preclude entry into the study.
- History of having a significant illness within the 2 weeks prior to screening visit. Participants can screen after illness is resolved for two weeks.
- History of clinically significant electrocardiogram abnormalities or clinically significant abnormalities from the screening electrocardiogram.
- G6PD deficiency
- History of hemolytic anemia or methemoglobinemia
- History of severe drug hypersensitivity including a severe allergic reaction, anaphylaxis or convulsions following any medication, vaccination or infusion.
- History of drug or alcohol abuse in the 12 months prior to screening or evidence at screening visit
- Use of nicotine containing products within 30 days prior to screening
- Positive blood test for HBsAg, HCV, or HIV-1
- Participation in a clinical study of another investigational product within 30 days prior to study enrollment, or planning to begin such participation during the study.
- Employment under the direct supervision of the investigators or study staff.
- Receipt of any vaccination within 7 days of dosing.
- Febrile illness within 48 hours of dosing
- Use of any prescription medication within 14 days prior to study drug administration.
- Use of nonprescription drugs, including vitamins, antacids, and herbal and dietary supplements within 7 days prior to study drug administration. Acetaminophen may be used at doses of ≤ 1 g/day, and ibuprofen may be used at doses of ≤ 1.2 g/day.
- Consumption of pomegranate, grapefruit or other citrus fruits or their juices within 7 days prior to study drug administration.
- Use of nicotine containing products from screening to study drug administration.
- Consumption of alcohol within 24 hours prior to study drug administration.
Inclusion Criteria For participants in multi-dose cohort only:
- Agrees not to receive any vaccination within 7 days prior to Day 1 and through Day 10.
- Agrees not to use nonprescription drugs, including vitamins, antacids, and herbal and dietary supplements within 7 days prior to Day 1 and through Day 10. Acetaminophen may be used at doses of ≤ 1 g/day, and ibuprofen may be used at doses of ≤ 1.2 g/day.
- Agrees not to use nicotine containing products from screening through Day 10.
- Agrees not to consume alcohol for the 24 hours prior to Day 1 and through Day 10.
- Agrees not to eat pomegranate, grapefruit or other citrus fruits or drink their juices within 7 days prior to Day 1 and through Day 10.
- Agrees to limit caffeine to no more than 200 mg on Days 1, 2, and 3.
- Agrees not to eat or drink (except water) for 10 hours before the Days 1, 2, and 3 visits and have no water for the hour prior to dosing on each of those days.
Note: As with the single dose study, sexually active must agree to be abstinent or use condoms for the duration of the study (through the Day 14 visit).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm
Participants will receive SJ733, an investigational drug developed at St. Jude Children's Research Hospital, and cobicistat.
|
SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4.
It will be administered as a single, multi, or boosted oral dose.
Other Names:
Commercially available cobicistat 150 mg tablets will be used.
It will be administered as a single oral dose together with SJ733.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicity (DLT)
Time Frame: From baseline up to minimum of 7 days post-dose
|
Number of DLT events will be described at each study dose level.
DLT is defined as possibly, probably, or definitely related Grade 4 event, possibly, probably or definitely related Grade 3 event, or possibly, probably, or definitely related Grade 2 methemoglobinemia or anemia (attributed to hemolysis) events.
|
From baseline up to minimum of 7 days post-dose
|
Maximum tolerated dose (MTD)
Time Frame: 7 days after the last dose administration
|
MTD is defined as the dose level prior to the dose cohort that 2 or more Grade 2 methemoglobinemia or anemia (attributed to hemolysis) OR any related Grade 3 OR any Grade 4, study drug adverse event (AE) occurred in.
|
7 days after the last dose administration
|
Drug absorption
Time Frame: From baseline through 7 days post-dose
|
Drug absorption of SJ733 and its metabolite will be reported.
|
From baseline through 7 days post-dose
|
Drug clearance
Time Frame: From baseline through 7 days post-dose
|
Drug clearance of SJ733 and its metabolite will be reported.
|
From baseline through 7 days post-dose
|
Drug volume of distribution
Time Frame: From baseline through 7 days post-dose
|
Drug volume of distribution of SJ733 and its metabolite will be reported.
|
From baseline through 7 days post-dose
|
Area under the curve (AUC)
Time Frame: From baseline through 7 days post-dose
|
AUC of SJ733 and its metabolite will be reported.
|
From baseline through 7 days post-dose
|
Time above threshold concentration
Time Frame: From baseline through 7 days post-dose
|
Time above threshold concentration of SJ733 and its metabolite will be reported.
|
From baseline through 7 days post-dose
|
Maximum drug concentration (Cmax)
Time Frame: From baseline through 7 days post-dose
|
Cmax of SJ733 and its metabolite will be reported.
|
From baseline through 7 days post-dose
|
Dose level of SJ733
Time Frame: 14 days after the last dose administration
|
The dose chosen for the phase 1b trial will be no greater than the MTD and provide an exposure (AUC and time above threshold concentration) that equates (using applicable scaling) with those that provided maximum parasitological effect in the gold standard rodent model.
|
14 days after the last dose administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug absorption in the fed cohort
Time Frame: From baseline through 7 days post-dose
|
Drug absorption of SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake.
|
From baseline through 7 days post-dose
|
Drug clearance in the fed cohort
Time Frame: From baseline through 7 days post-dose
|
Drug clearance of SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake.
|
From baseline through 7 days post-dose
|
Drug volume of distribution in the fed cohort
Time Frame: From baseline through 7 days post-dose
|
Drug volume of distribution of SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake.
|
From baseline through 7 days post-dose
|
Area under the curve (AUC) in the fed cohort
Time Frame: From baseline through 7 days post-dose
|
AUC of SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake.
|
From baseline through 7 days post-dose
|
Time above threshold concentration in the fed cohort
Time Frame: From baseline through 7 days post-dose
|
Time above threshold concentration SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake.
|
From baseline through 7 days post-dose
|
Maximum drug concentration (Cmax) in the fed cohort
Time Frame: From baseline through 7 days post-dose
|
Drug absorption of SJ733 and its metabolite in the fed cohort will be reported to assess the impact of food intake.
|
From baseline through 7 days post-dose
|
Collaborators and Investigators
Investigators
- Principal Investigator: Aditya H. Gaur, MD, St. Jude Children's Research Hospital
Publications and helpful links
General Publications
- Gaur AH, Panetta JC, Smith AM, Dallas RH, Freeman BB 3rd, Stewart TB, Tang L, John E, Branum KC, Patel ND, Ost S, Heine RN, Richardson JL, Hammill JT, Bebrevska L, Gusovsky F, Maki N, Yanagi T, Flynn PM, McCarthy JS, Chalon S, Guy RK. Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development. EBioMedicine. 2022 Jun;80:104065. doi: 10.1016/j.ebiom.2022.104065. Epub 2022 May 19.
- Gaur AH, McCarthy JS, Panetta JC, Dallas RH, Woodford J, Tang L, Smith AM, Stewart TB, Branum KC, Freeman BB 3rd, Patel ND, John E, Chalon S, Ost S, Heine RN, Richardson JL, Christensen R, Flynn PM, Van Gessel Y, Mitasev B, Mohrle JJ, Gusovsky F, Bebrevska L, Guy RK. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Lancet Infect Dis. 2020 Aug;20(8):964-975. doi: 10.1016/S1473-3099(19)30611-5. Epub 2020 Apr 8.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Cobicistat
Other Study ID Numbers
- BUZZOFF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on SJ733
-
R. Kiplin GuyEisai Inc.; Asociacion Civil Selva Amazonica; Global Health Innovative Technology...CompletedMalaria, Falciparum | Malaria, VivaxPeru
-
Medicines for Malaria VentureQ-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...CompletedPlasmodium Falciparum MalariaAustralia